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Infective endocarditis is a life threatening disease with 30% one
year mortality1 that affects 3-10 per 100 000 population per
year—the average general practitioner will see one case every
20 years.2 Infective endocarditis occurs when bacteria enter the
bloodstream through the mouth, gut, or skin, and replicate within
the heart to form a “vegetation,” which is usually adherent to
one of the valves (fig 1⇓, fig 2⇓). Specific patient subgroups
are at increased risk of infective endocarditis as a result of
damaged cardiac endothelium, abnormal blood flow, intracardiac
prosthetic material, immunosuppression, or recurrent
bacteraemia (box 1).3 4
Streptococci which colonise the mouth are the causative
organism in 20%-40% of patients with infective endocarditis,5 6
and poor oral hygiene is a known risk factor.7 Invasive dental
procedures that disrupt gingival integrity allow oral bacteria to
access the circulation, which can lead to infective endocarditis
in at-risk patients. Strategies that prevent bacteraemia or
bacterial adherence might be expected to reduce the risk of
infective endocarditis.
Oral antibiotic prophylaxis has been used for more than 50 years
as a preventative strategy in at-risk patients undergoing invasive
dental procedures.8 The efficacy of antibiotic prophylaxis has
been confirmed in animal models,9 however the clinical evidence
base is weak and its use has been challenged in the last decade.
Nonetheless, guidelines from the European Society of
Cardiology and the American Heart Association/American
College of Cardiology committees continue to advocate
antibiotic prophylaxis for those at highest risk.10 11
Controversially, in 2008 the UK National Institute for Health
and Care Excellence (NICE) advised complete cessation of
antibiotic prophylaxis to prevent infective endocarditis.12 In this
article, we outline the evidence for and against antibiotic
prophylaxis, the controversy surrounding its use, and ongoing
research in the field. We provide a framework for clinical
practice in the context of uncertainty.
What is the evidence of uncertainty?
Do invasive dental procedures cause infective
endocarditis?
Invasive dental procedures cause bacteraemia, which is a
necessary precursor to infective endocarditis,13 but it is unclear
if dental interventions cause infective endocarditis. In a
prospective Dutch cohort of 427 cases of infective endocarditis,
only 31 (11%) had undergone an invasive procedure (medical
or dental) within the preceding 30 days.14 In a French case
control study of 171 infective endocarditis cases and matched
controls, there was no substantial difference in the number of
dental procedures in the preceding three months (odds ratio 1.2,
95% confidence interval 0.7 to 2.1).15 In a similar case control
study of 273 cases and matched controls, an invasive dental
procedure was undertaken during the three months before
infective endocarditis diagnosis in 36 cases (13.2%) and 27
controls (9.9%) (odds ratio 1.6, 95% confidence interval 0.8 to
3.4), suggesting no statistically significant risk associated with
dental intervention.4 More recently, a retrospective analysis of
739 patients in Taiwan found no increased likelihood of
exposure to dental procedures in the three month period before
infective endocarditis hospitalisation, compared with a control
period when infective endocarditis did not develop.16 These
studies suggest that invasive dentistry is not the trigger for most
cases of infective endocarditis, however the studies were
conducted in populations already using antibiotic prophylaxis,
which might mask an association. All studies were
underpowered to address the question.4-15
If invasive dental procedures are not the main trigger, an
alternative explanation is that community acquired infective
endocarditis might arise from low level bacteraemia occurring
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What you need to know
Patients with prosthetic heart valves, previous infective endocarditis, and some types of congenital heart disease are at highest risk of
infective endocarditis
Invasive dental procedures cause bacteraemia, which can be complicated by infective endocarditis in those at increased risk of the
disease
Antibiotic prophylaxis reduces the incidence of bacteraemia, but high level studies confirming that this reduces the incidence of infective
endocarditis are lacking
Warn high risk patients undergoing high risk dental interventions of the risk of infective endocarditis. Offer these patients antibiotic
prophylaxis, and discuss with them the risks and benefits of this option
Where patients are at moderate risk, encourage preventative measures, such as maintaining good oral hygiene and infection control,
and discourage tattooing or piercing
Box 1: Risk factors for infective endocarditis
Cardiac
Prosthetic heart valve*
Previous infective endocarditis*
Congenital heart disease* †
Rheumatic heart disease
Degenerative valve disease
Cardiac transplant with valvulopathy
Implantable electronic cardiac device (pacemaker or defibrillator)
Hypertrophic cardiomyopathy
Non-cardiac
Haemodialysis
Diabetes mellitus
Injected drug use
Indwelling venous catheters
Immunosuppression
Poor oral hygiene
*at highest risk
†see specific subgroups in ⇓
as bacteria translocate across the relatively permeable oral
mucosa in the course of everyday activities, such as chewing,
flossing, or tooth brushing (especially in those with poor oral
hygiene or periodontal disease).17 The cumulative burden of this
“everyday” bacteraemia is several orders of magnitude greater
than rare episodes of “surgical” bacteraemia that result from
dental procedures. This could explain why many cases of
infective endocarditis arise in the absence of a preceding dental
intervention.18
In the context of this uncertainty, a French population based
cohort study published in this edition of the The BMJ is timely.19
Among 138 876 adults with prosthetic heart valves, there was
no statistically significant increase in the risk of oral
streptococcal infective endocarditis in the three month period
after an invasive dental procedure (risk ratio 1.25, 95%
confidence interval 0.82 to 1.82, P=0.26) compared with
controls exposed to non-invasive dental procedures. Findings
were similar in the large subset of 21 471 patients undergoing
procedures without antibiotic prophylaxis (49.9% of all invasive
dental procedures; risk ratio 1.57, 95% confidence interval 0.90
to 2.53, P=0.08). Over median follow-up of 1.7 years, there
were 267 cases—an incidence of oral streptococcal infective
endocarditis of 93.7 per 100 000 person-years and overall rate
of oral streptococcal infective endocarditis of 1.4 cases per 10
000 invasive dental procedures.
However, these findings were not replicated in a case crossover
analysis in the same study, in which each of the cases served as
their own control. The analysis compared the frequency of
invasive dental procedures in the three months before a diagnosis
of infective endocarditis with earlier control periods. Exposure
to invasive dental procedures was substantially more frequent
during case than control periods (5.1% v 3.2%, odds ratio 1.66,
95% confidence interval 1.05 to 2.63, P=0.03).
This description of a large, representative, population at risk of
infective endocarditis is a valuable addition to the evidence
base. The apparently discordant findings between analyses might
be explained by unrecognised differences between the overall
cohort and infective endocarditis cases: for example, oral
hygiene and dental status were unknown on account of the
limitations of coding. The case crossover analysis is likely to
better control for individual patient risk factors and suggests
that invasive dental procedures are associated with oral
streptococcal infective endocarditis in some patients.
Importantly, however, both analyses support the concept that
most cases of infective endocarditis arise independently of
invasive dental procedures.
If invasive dental procedures cause infective
endocarditis in some patients, does antibiotic
prophylaxis reduce the risk?
Antibiotic prophylaxis has been shown to reduce bacteraemia
in multiple studies: a recent meta-analysis of 21 trials of
antibiotic prophylaxis in patients undergoing dental intervention
showed a substantial reduction in the incidence of post
procedural bacteraemia (risk ratio 0.53, 95% confidence interval
0.49 to 0.57, P<0.01).20 It is not clear, however, whether
reduction in the incidence of bacteraemia translates into
reduction in the incidence of infective endocarditis.
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No randomised controlled trial of antibiotic prophylaxis for
prevention of infective endocarditis has ever been conducted.
The evidence base evaluating antibiotic prophylaxis is therefore
derived from observational data. Meta-analysis of three
case-control studies15-22 showed no statistically significant
association between cases and failure to use antibiotic
prophylaxis (odds ratio 0.59, 95% confidence interval 0.27 to
1.30, P=0.14).20 However, these studies were underpowered to
address this question and were at high risk of intrinsic bias, so
the overall level of evidence is weak.20 Many of the patients
within these studies were not high risk and would not be eligible
for antibiotic prophylaxis according to current guidelines. The
study published in this issue found that the crude incidence of
infective endocarditis in the three months after an invasive dental
procedure was lower in patients taking antibiotic prophylaxis
(78.1 [95% confidence interval 1.6 to 154.6] v 149.5 [95%
confidence interval 56.8 to 242.2] per 100 000 person years).
These rates were not statistically significantly different,
however, possibly because of the small number of cases in each
group.19 In a moderate size retrospective cohort study, a
protective effect of antibiotic prophylaxis was identified in high
risk patients with a prosthetic heart valve undergoing invasive
procedures (a proportion of which were dental).23 Similarly, a
population based cohort study found a protective effect of
antibiotic prophylaxis in individuals with cardiac conditions,
using extrapolated estimates of the incidence of infective
endocarditis after protected or unprotected dental procedures.24
An alternative observational approach has been to examine
changes in the incidence of infective endocarditis after guideline
amendments to restrict the use of antibiotic prophylaxis. In
2008, NICE recommended the cessation of antibiotic
prophylaxis in the UK for all patients. Subsequent follow-up
showed an 88% reduction in the use of antibiotic prophylaxis
and an increase in the incidence of infective endocarditis above
the projected historical trend (corresponding to an additional
35 cases in England per month).2 This study, however, lacked
microbiological data to confirm that this change was secondary
to an increase in oral streptococci infective endocarditis. Similar
studies in Europe and the USA have shown varying results, but
in the context of continued antibiotic prophylaxis in high risk
patients (table 1⇓). In July 2016, NICE updated its guidance to
indicate that antibiotic prophylaxis is not recommended
“routinely” and that “this amendment should make clear that in
individual cases antibiotic prophylaxis may be appropriate.”36
What are the risks and benefits of antibiotic
prophylaxis?
There are legitimate concerns that the risks and low
cost-effectiveness of antibiotic prophylaxis might outweigh the
benefits.37 Widespread use of antibiotic prophylaxis might
contribute to antibiotic resistance, although this has not been
linked specifically to single dose antibiotic prophylaxis, and the
risk of anaphylaxis might exceed the protective effect of
antibiotic prophylaxis. However, recent analysis of UK adverse
event reporting identified only two adverse events per year and
no deaths from antibiotic prophylaxis with single dose
amoxicillin, and clindamycin antibiotic prophylaxis (used in
penicillin allergic patients) resulted in twice as many adverse
events and one death every three years.38 Risk benefit analysis
suggests that reinstatement of antibiotic prophylaxis for those
at moderate or high risk of infective endocarditis would be
associated with beneficial clinical effects overall.39 Moreover,
such a change would lead to cost savings of £5.5-£8.2 million
and health gains of >2600 quality adjusted life years in England
per annum.40
Is ongoing research likely to provide
relevant evidence?
Infective endocarditis rarely arises after a dental intervention,
so conducting a randomised controlled trial is challenging. It is
unclear whether even an international multicentre trial would
be able to recruit sufficient numbers of patients in a pragmatic
timescale. In the last decade, national funding agencies in both
the USA and UK have balked at the projected cost. Since the
standard of care recommended by the European Society of
Cardiology and American Heart Association/American College
of Cardiology guidelines is that patients at highest risk of
infective endocarditis should receive antibiotic prophylaxis, it
is unclear whether a placebo controlled, “no antibiotic
prophylaxis” trial would receive international ethical approval.
In this context, the priority is to further clarify the link between
infective endocarditis and invasive dental procedures. To do
this, we are conducting an observational study, the IDEA Study,
to link NHS Digital hospital admissions data to the NHS
Business Services Authority Dental Database and to determine
whether the frequency of invasive dental procedures is higher
in the three months before the diagnosis of infective
endocarditis, compared with earlier three month “control”
periods (https://www.journalslibrary.nihr.ac.uk/programmes/
hta/155732/#/). This study will be highly powered to assess the
link between invasive dentistry and infective endocarditis: in
the proposed period of study between April 2009 and March
2015, there are data for 10 593 infective endocarditis admissions
and 90.6 million invasive dental procedures. The study will be
conducted in the English population, for whom antibiotic
prophylaxis was not recommended during this period, thereby
fully exposing any potential link between invasive dental
procedures and infective endocarditis and the case crossover
design will reduce any effect from residual confounders.
Refuting a link between dental interventions and infective
endocarditis would logically support a move away from
antibiotic prophylaxis as a preventative strategy. Conversely,
confirmation of the link would provide further justification for
a randomised trial.
What should we do in light of the
uncertainty?
The first step is to risk stratify the patient (fig 3⇓). Consistent
with European Society of Cardiology and American Heart
Association/American College of Cardiology guidelines, we
advocate that antibiotic prophylaxis is only considered for high
risk patients: those with prosthetic valves, previous infective
endocarditis, or certain types of congenital heart disease. We
also suggest dental risk stratification: high risk procedures are
those in which there is manipulation of the gingival or periapical
region of the teeth (fig 3⇓).
If both the patient and dental procedure are high risk, it is
reasonable to offer the option of antibiotic prophylaxis. When
offering antibiotic prophylaxis,
• outline what is known about the potential risks and benefits
• explain that the evidence base is weak
• reassure the patient that the overall risk of infective
endocarditis after a dental intervention is extremely low
(even in those at high risk).
For patients who choose antibiotic prophylaxis, we advise single
dose amoxicillin 3 g given orally 60 minutes before the
procedure, or clindamycin 600 mg in those who are allergic to
penicillin.41
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Educate patients at risk (including those with native valve
disease or a bicuspid aortic valve, who are at moderate risk) of
the importance of disease prevention. Advise patients on
• good oral hygiene with at least yearly dental review
• infection control including disinfection of cutaneous
wounds, curative antibiotics for any focus of bacterial
infection
• discourage tattooing or piercing
• the symptoms of infective endocarditis for patients at risk42
(see supplementary file: Patient information leaflet on
infective endocarditis).
Early diagnosis of infective endocarditis can be life saving but
it requires a high index of suspicion among dentists, general
practitioners, and hospital doctors.
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Recommendations for further research
A properly powered randomised controlled trial of antibiotic prophylaxis in dental procedures would resolve the current controversy over its
efficacy in reducing the risk of developing infective endocarditis.
A registry of all infective endocarditis cases and associated microbiology would also greatly further our knowledge.
The IDEA study mentioned above will hopefully determine if there really is a link between invasive dental procedures and infective endocarditis.
Since the majority of endocarditis cases caused by oral bacteria appear to result from daily activities and poor oral hygiene rather than
invasive dental procedures, we also need further research to elucidate the link between poor oral hygiene, periodontal disease, and infective
endocarditis and to identify other methods, besides antibiotic prophylaxis, that could prevent infective endocarditis.
How patients were involved in this article
We are very grateful for comments and suggested changes to this article from two individuals whose spouses died of infective endocarditis,
which developed after dental intervention.
Through the charity Heart Valve Voice (https://www.heartvalvevoice.com/) we approached patients at risk of infective endocarditis, who
suggested that overall awareness of infective endocarditis is poor. Individual patients have found a lack of consensus regarding antibiotic
prophylaxis and are consequently seeking unfiltered internet advice.
Search strategy
The search strategy for our systematic review addressing the efficacy of antibiotic prophylaxis before invasive dental procedures has been
published in full at http://heart.bmj.com/content/early/2017/02/17/heartjnl-2015-309102.long.20
In summary, using subject headings or title/abstract keywords for bacterial endocarditis, antibiotics, and prophylaxis, we searched Medline,
Medline In-Process (OvidSP), Embase (OvidSP), Cochrane Central Register of Controlled Trials (Cochrane Library, Wiley), Cochrane
Database of Systematic Reviews, Database of Abstracts of Reviews of Effects (Cochrane Library, Wiley), Science Citation Index Expanded
and Conference Proceedings Citation Index—Science (Web of Science Core Collection), Clinicaltrials.gov, and the WHO International
Clinical Trials Registry Platform from inception up to 25 February 2016.
Education into practice
How do you identify patients at high and moderate risk of infective endocarditis? How could you make this process more robust?
Has this article given you new ideas about how to discuss antibiotic prophylaxis for invasive dental procedures with patients at risk of
infective endocarditis?
Do you routinely give all high risk patients an infective endocarditis patient leaflet like that in the supplementary file attached to this
article?
Are you aware of the cardinal symptoms of infective endocarditis? Do you make sure that your high risk patients are aware of how to
spot these symptoms and what to do if they occur?
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Table
Table 1| Time trend studies examining effect of antibiotic prophylaxis guideline change on the incidence of infective endocarditis (IE)
Guideline
time point
Increase
in rate of
Increased
incidence
Guideline
change. Level
Study periodDiagnosisPopulationRegion,
country
Paper/abstractPMIDFirst
author,
year identifiedchange ofafter-guideline
change
of antibiotic
prophylaxis
restriction
by
change
incidence
after
guideline point
analysis?
NANoNo
AHA/ACC April
2007.
Relative
restriction2003-2014
All cases: acute
and subacute
bacterial IE
Children ≤18
identified from
Paediatric
Health
Information
System
USAPaper27418041
Bates
201625
Database (29
hospitals)
NANANo
AHA/ACC April
2007.
Relative
restriction1999-2010
All cases:
principal or
secondary
discharge dx of
IEAdults ≥65USAPaper23994421
Bikdeli
201326
YesYesYes
NICE March
2008.
Total restriction
January 1,
2000-March 31,
2013
All cases:
primary dx
acute or
subacute IEAllUKPaper25467569
Dayer
20152
&
Thornhill
201127*
NANANo
AHA/ACC April
2007.
Relative
restriction
January 1
1999-December
31 2013VGS IEAdults ≥18
Olmsted
County,
Minnesota,
USAPaper26141329
DeSimone
201528
&
De
Simone
201229*
NANANo
French
guideline
restrictions
2002.
Relative
restriction
Survey years
1991, 1999,
2008
All cases of IE
and subgroups
by causative
organismAdults ≥20
Greater
Paris,
Lorraine, and
Rhône-Alpes
regions of
FrancePaper22624837
Duval
201230
NoYesYes
ESC
October 2009.
Relative
restriction2005-2014
IE caused by
Streptococcus
and
Staphylococcus
(reported
separately)
All patients
hospitalised
with acute or
subacute IEGermanyPaper27816113
Keller
201631
NoYes
Total IE
increase,
decrease in
VGS
AHA/ACC April
2007.
Relative
restriction
April
2002-March
2013
All
hospitalisations
with primary dx
of IE
All patients
hospitalised
with acute or
subacute IE
as main
diagnosis
Canada
(except
Quebec and
the Northern
Territories)Paper26868840
Mackie
201632
Not
performedYesYes
AHA/ACC April
2007.
Relative
restriction2000-2011
All cases of IE
and subgroups
by causative
organism
Patients in
Nationwide
Inpatient
Sample with
ICD codes for
IEUSAPaper25975469
Pant
201533
NANANo
AHA/ACC April
2007.
Relative
restriction2002-2012All cases
All patients
hospitalised
with IE in
State of QatarQatarAbstractNA
Salam
201434
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Table 1 (continued)
Guideline
time point
identified
by
change
point
analysis?
Increase
in rate of
change of
incidence
after
guideline
Increased
incidence
after-guideline
change
Guideline
change. Level
of antibiotic
prophylaxis
restriction
Study periodDiagnosisPopulationRegion,
country
Paper/abstractPMIDFirst
author,
year
NAYes
Yes, substantial
increase in VGS
ESC
October 2009.
Relative
restriction2005-2011All cases of IE
All patients
identified from
the national
healthcare
insurance
databaseNetherlandsPaperPending
van den
Brink
201635
*Earlier publications from same research group using same methodology. Study with longer follow-up used for analysis
AHA/ACC: American Heart Association/American College of Cardiology
ESC: European Society of Cardiology
VGS: Viridans group streptococci
ICD: International Classification of Diseases
Reproduced with permission from 20
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Figures
Fig 1 Pathogenesis of infective endocarditis
Fig 2 Infective endocarditis. Vegetation can be seen on the mitral valve (arrow)
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Fig 3 Identifying patients at risk of infective endocarditis who might benefit from antibiotic prophylaxis and other preventative
measures
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